Pharma channel feed

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

6 years ago

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

6 years ago

Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

6 years ago
People

Ail­ing Mallinck­rodt's drug for rare, life-threat­en­ing re­nal con­di­tion clears piv­otal study

6 years ago
R&D

FDA en­dors­es new reg­i­men for dead­ly drug-re­sis­tant tu­ber­cu­lo­sis ram­pant in de­vel­op­ing world

6 years ago
R&D
FDA+

Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

6 years ago
R&D

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

6 years ago
R&D

As ne­go­ti­a­tions with Eng­land la­bor on, Scot­land re­jects rou­tine use of Ver­tex's cys­tic fi­bro­sis drugs

6 years ago
FDA+

Make that 2 new US Big Phar­ma chiefs to­day, as No­var­tis re­makes top team

6 years ago
People

Hu­mana takes aim at Mallinck­rodt's 'ill-got­ten' Ac­thar gains in law­suit

6 years ago
FDA+

Am­gen at­tor­neys win a megablock­buster patent case, deal­ing No­var­tis a se­vere set­back on biosim­i­lars play

6 years ago

US sen­a­tors ac­cuse No­var­tis ex­ecs of greed for hid­ing ma­nip­u­lat­ed Zol­gens­ma da­ta — and the next step could af­fect the in­dus­try

6 years ago
FDA+

As­traZeneca's flag­ship Tagris­so helps lung can­cer pa­tients live longer in piv­otal study

6 years ago
R&D

Sarep­ta shares slammed on re­port gene ther­a­py Duchenne MD pa­tient was hos­pi­tal­ized, but the com­pa­ny says it is 'er­ro­neous'

6 years ago
R&D

FDA Ad­Com backs Gilead­'s move to ex­pand De­scovy la­bel — but stops short of en­dors­ing broad PrEP use

6 years ago
R&D

CMS will now cov­er pricey CAR-T ther­a­pies for Medicare pa­tients

6 years ago
FDA+

Loxo chief Josh Bilenker steps in (tem­porar­i­ly) to head on­col­o­gy R&D at Eli Lil­ly as Levi Gar­raway steps out

6 years ago
People

Te­va to lose CFO, with turn­around still un­der con­struc­tion

6 years ago
People

What’s a late-stage IL-23 drug worth these days? We’re about to find out

6 years ago
R&D

As­traZeneca, Mer­ck her­ald PhI­II prostate can­cer win for Lyn­parza — over­tak­ing Clo­vis, J&J in PARP race

6 years ago
R&D

Faced with an­oth­er ethics scan­dal, No­var­tis CEO Vas Narasimhan as­sures an­a­lysts they tried to do 'the right thing'

6 years ago
FDA+

Gilead faces a hur­dle in its race for big, add-on OK for De­scovy as gener­ic Tru­va­da ri­vals loom

6 years ago
R&D

In draft guid­ance, NICE fails to back Clo­vis's PARP in­hibitor Rubra­ca

6 years ago
FDA+

Rac­ing af­ter the lead­ers, Eli Lil­ly's mi­graine drug clears an­oth­er piv­otal study

6 years ago
First page Previous page 268269270271272273274 Next page Last page
A service from the Financial Times